2. Academic Validation
  3. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor

Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor

  • Antiviral Res. 2006 Jun;70(2):17-20. doi: 10.1016/j.antiviral.2005.12.006.
G Sévigny 1,  B Stranix,  B Tian,  A Dubois,  G Sauvé,  C Petropoulos,  Y Lie,  N Hellmann,  B Conway,  J Yelle
Affiliations

Affiliation

  • 1 Procyon Biopharma Inc., Montreal, Canada.
PMID: 16473417 DOI: 10.1016/j.antiviral.2005.12.006
Abstract

The HIV Protease Inhibitor P-1946 is a member of a novel family of l-Lysine derivatives. The compound is a specific HIV-1 protease inhibitor that has potent and selective in vitro Antiviral activity (EC50 152 nM) against a range of isolates resistant to commercially available Protease Inhibitors. The presence of at least four primary and four secondary drug resistance mutations is required to achieve greater than four-fold resistance to P-1946. P-1946's favorable resistance profile makes it a good lead for the development of new agents active against existing PI-resistant virus in treatment-experienced patient.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z